The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Pancancer survival analysis of cancer hallmark genes
Open accessAbstract
Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan–Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26, p < 1E−16), RUNX1 (sustaining proliferative signaling, HR 2.96, p = 3.1E−10) and SERPINE1 (inducing angiogenesis, HR 3.36, p = 1.5E−12) in low grade glioma, CDK1 (cell death resistance, HR = 5.67, p = 2.1E−10) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38, p = 2.4E−05) and EREG (enabling replicative immortality, HR 3.23, p = 2.1E−07) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45, p = 2.8E−07) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81, p = 5.8E−05) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kaplan–Meier analysis using public breast cancer meta-analysis database11,30 reveals that TNBC patients with higher hypoxia gene signature are associated with worse disease outcomes, including both overall survival (OS) and distant metastasis-free survival (DMFS), compared to those with lower expression of hypoxia gene signature (Fig. 1h).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,438
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G. M., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M. A. M., Gelder, M. E. M., Yu, J. X., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,831
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Cited by
Sorted by citations
Items 101–200 of 1,000
Alhujaily, M. M., Abbas, H., Xue, M., de la Fuente, A., Rabbani, N., & Thornalley, P. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.748698 · Cited by 29
PPP1R14B Is a Prognostic and Immunological Biomarker in Pan-Cancer
Deng, M., Peng, L., Li, J., Liu, X., Xia, X., & Li, G. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.763561 · Cited by 29
Adinew, G. M., Messeha, S. S., Taka, E., & Soliman, K. F. A. (2022) · Cancers · doi:10.3390/cancers14215180 · Cited by 29
Eid, R. A., Soltan, M. A., Eldeen, M. A., Shati, A. A., Dawood, S. A., Eissa, M., Zaki, M. S. A., Algahtani, M., Theyab, A., Abdel‐Daim, M. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214102 · Cited by 29
Kannan, B., Pandi, C., Pandi, A., Jayaseelan, V. P., & Arumugam, P. (2024) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2024.105926 · Cited by 29
Khan, A., & Zhang, X. (2022) · Bioengineering · doi:10.3390/bioengineering9080406 · Cited by 29
Phosphorylation of CAP1 regulates lung cancer proliferation, migration, and invasion
Zeng, J., Li, X., Liang, L., Duan, H., Xie, S., & Wang, C. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03819-9 · Cited by 28
Liu, Y., Yang, Y., Jiang, L., Xu, H., & Wei, J. (2021) · Journal of Oncology · doi:10.1155/2021/5680968 · Cited by 28
Identification of pyroptosis-related signature for cervical cancer predicting prognosis
Zhou, C., Li, C., Zheng, Y., & Liu, X. (2021) · Aging · doi:10.18632/aging.203716 · Cited by 27
MicroRNA-125b-5p Correlates With Prognosis and Lung Adenocarcinoma Progression
Tang, L., Yuan, Y., Zhai, H., Wang, J., Zhang, D., Liang, H., Shi, Y., Duan, L., & Jiang, X. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788690 · Cited by 28
Sun, K., Chen, R., Li, J., & Luo, Z. (2022) · Scientific Reports · doi:10.1038/s41598-022-19247-9 · Cited by 28
Lu, B., Chen, X., Liu, X., Chen, J., Qin, H., Chen, S., & Zhao, Y. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03802-z · Cited by 33
RFC3 serves as a novel prognostic biomarker and target for head and neck squamous cell carcinoma
Keerthana Reddy, A. V. S., Pandi, C., Kannan, B., Pandi, A., Jayaseelan, V. P., & Arumugam, P. (2023) · Clinical Oral Investigations · doi:10.1007/s00784-023-05316-4 · Cited by 28
SmulTCan: A Shiny application for multivariable survival analysis of TCGA data with gene sets
Özhan, A., Tombaz, M., & Konu, Ö. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104793 · Cited by 28
Fernández-Avila, L., Castro-Amaya, A. M., Molina-Pineda, A., Hernández‐Gutiérrez, R., Jave‐Suárez, L. F., & Aguilar‐Lemarroy, A. (2023) · Biomedicines · doi:10.3390/biomedicines11102655 · Cited by 28
Yu, Z., He, H., Chen, Y., Ji, Q., & Sun, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-90126-5 · Cited by 27
FGF signalling facilitates cervical cancer progression
Mahmood, H.-T.-N. A., Bort, E. T., Walker, A. J., Grose, R. P., & Chioni, A. (2021) · FEBS Journal · doi:10.1111/febs.16331 · Cited by 28
CXCL8 is a prognostic biomarker and correlated with TNBC brain metastasis and immune infiltration
Shen, Y., Zhang, B., Wei, X., Guan, X., & Zhang, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108454 · Cited by 26
Wang, S., Wang, T., Zhang, X., Cheng, S., Chen, C., Yang, G., Wang, F., Wang, R., Zhang, Q., Yang, D., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01176-3 · Cited by 27
Ramalingam, P. S., Priyadharshini, A., Emerson, I. A., & Arumugam, S. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1107128 · Cited by 25
Tumor Promoting Effect of BMP Signaling in Endometrial Cancer
Fukuda, T., Fukuda, R., Miyazono, K., & Heldin, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157882 · Cited by 26
Wu, B., & Xi, S. (2021) · BMC Cancer · doi:10.1186/s12885-021-08674-y · Cited by 27
Shen, M., Zhang, R., Jia, W., Zhu, Z., Zhao, L., Huang, G., & Liu, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-021-04488-9 · Cited by 26
Weed, D. T., Zilio, S., McGee, C. S., Marnissi, B., Sargi, Z., Franzmann, E. J., Thomas, G. R., Leibowitz, J. M., Nicolli, E. A., Arnold, D., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0379 · Cited by 27
PKM2 is a potential prognostic biomarker and related to immune infiltration in lung cancer
Yin, L., Shi, J., Zhang, J., Lin, X., Jiang, W., Zhu, Y., Song, Y., Lu, Y., & Ma, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-49558-4 · Cited by 26
Lin, Z., Xie, Y., Zhao, M.-C., Hou, P.-P., Tang, J., & Chen, G. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02173-7 · Cited by 26
Cao, B., Deng, H., Cui, H., Zhao, R., Li, H., Wei, B., & Chen, L. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02193-3 · Cited by 25
Xu, Z., Jin, H. Z., Duan, X., Liu, H., Zhao, X., Fan, S., Wang, Y., & Yao, T. (2021) · Environmental Toxicology · doi:10.1002/tox.23370 · Cited by 25
Zhang, X., & Yang, Q. F. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.705828 · Cited by 25
Xu, D., Wu, J., Dong, L., Luo, W., Li, L., Tang, D., & Liu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.738607 · Cited by 25
Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells
Maietta, I., Martínez-Pérez, A., Álvarez, R., de Lera, Á. R., González‐Fernández, Á., & Simón‐Vázquez, R. (2022) · Pharmaceuticals · doi:10.3390/ph15070824 · Cited by 25
Role of miR-944/MMP10/AXL- axis in lymph node metastasis in tongue cancer
Dharavath, B., Butle, A. B., Pal, A., Desai, S., Upadhyay, P., Rane, A., Khandelwal, R., Manavalan, S., Thorat, R. A., Sonawane, K., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04437-6 · Cited by 25
Microbiome-transcriptome-histology triad enhances survival risk stratification in multiple cancers
He, B., Ma, Y., Wang, K., Bing, P., Ji, L., Tian, G., Liu, H., He, P., & Yang, J. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108703 · Cited by 24
ADAM15 correlates with prognosis, immune infiltration and apoptosis in hepatocellular carcinoma
Xu, J. H., Guan, Y. J., Zhang, Y. C., Qiu, Z. D., Zhou, Y., Chen, C., Yu, J., & Wang, W. (2021) · Aging · doi:10.18632/aging.203425 · Cited by 25
Yang, J., Hao, R., Zhang, Y., Deng, H., Teng, W., & Wang, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02278-z · Cited by 24
Qu, Y.-Y., Guo, R.-Y., Luo, M.-L., & Zhou, Q. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.757582 · Cited by 24
LRRK2 correlates with macrophage infiltration in pan-cancer
Yan, J., Zhao, W., Yu, W., Cheng, H., & Zhu, B. (2021) · Genomics · doi:10.1016/j.ygeno.2021.11.037 · Cited by 24
Shi, X., Li, Y., Pan, S., Liu, X., Ke, Y., Guo, W., Wang, Y., Ruan, Q., Zhang, X., & Ma, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-05922-4 · Cited by 24
Fischer, T., Hartmann, O., Reissland, M., Prieto‐Garcia, C., Klann, K., Pahor, N., Schülein‐Völk, C., Baluapuri, A., Polat, B., Abazari, A., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00778-7 · Cited by 24
Qin, S., Liu, G., Jin, H., Chen, X., Jiang, H., Xiao, J., Qin, Y., Mao, Y., & Zhao, L. (2022) · Aging · doi:10.18632/aging.204217 · Cited by 24
Dioguardi, M., Cantore, S., Sovereto, D., Femina, L. L., Caloro, G. A., Spirito, F., Scacco, S., Cosola, M. D., Muzio, L. L., Troiano, G., et al. (2022) · Life · doi:10.3390/life12081269 · Cited by 24
Zhang, X., Xu, Q., Li, E., Shi, T., & Chen, H. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04607-w · Cited by 24
Dou, R., Han, L., Yang, C., Fang, Y., Zheng, J., Liang, C., Song, J., Chen, W., Huang, G., Zhong, P., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1432 · Cited by 24
CCPA: cloud-based, self-learning modules for consensus pathway analysis using GO, KEGG and Reactome
Nguyen, H., Pham, V.-D., Nguyen, H., Tran, B., Petereit, J., & Nguyen, T. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae222 · Cited by 24
Dreyer, T. F., Kuhn, S. P., Stange, C., Heithorst, N., Schilling, D., Jelsma, J., Sievert, W., Seitz, S., Stangl, S., Hapfelmeier, A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0327 · Cited by 23
Wang, Y., Dai, J., Zeng, Y., Guo, J., & Lan, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.752604 · Cited by 23
Yu, T., Zhang, T., Su, F., Li, Y., Li, S., Hou, X., & Wang, R. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/2805576 · Cited by 23
Zhang, Y., Liu, Q., Cui, M., Wang, M., Hua, S., Gao, J., & Liao, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774435 · Cited by 23
Ma, H.-M., Zhang, Q., Yang, X., Hu, Y., Zhang, J., Chen, L., Zhao, B., Yang, W., & Xu, R. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8168988 · Cited by 22
Guo, H., Jiang, S., Sun, H., Shi, B., Yan, L., Zhou, N., Zhang, D., & Guo, H. (2022) · Disease Markers · doi:10.1155/2022/9443407 · Cited by 23
Jacquier, V., Gitenay, D., Fritsch, S., Bonnet, S., Győrffy, B., Jalaguier, S., Linares, L. K., Cavaillès, V., & Teyssier, C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04277-3 · Cited by 23
Self-citationSengupta, I., Mondal, P., Sengupta, A., Mondal, A., Singh, V., Adhikari, S., Dhang, S., Roy, S., & Das, C. (2022) · FEBS Journal · doi:10.1111/febs.16544 · Cited by 23
Shi, Y.-X., Zhang, W., Dai, P.-H., Deng, J., & Tan, L.-H. (2022) · Scientific Reports · doi:10.1038/s41598-022-14250-6 · Cited by 23
Zheng, Y., Zhou, Z. Y., Wei, R., Chu, X., Zhang, H., Fan, T. T., Zheng, B. J., Li, C., & He, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03552-y · Cited by 23
Sabaa, M., Sharawy, M. H., El‐Sherbiny, M., Said, E., Salem, H. A., & Ibrahim, T. M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113675 · Cited by 23
Tan, Y., Zheng, T., Su, Z., Chen, M., Chen, S., Zhang, R., Wang, R., Li, K., & Na, N. (2023) · JCI Insight · doi:10.1172/jci.insight.162893 · Cited by 23
Li, S., Zhang, Z., Li, Z., Yang, L., Liu, J., Liu, Y., Liu, Y., Hou, Y., Mei, M., & Huang, Y. (2024) · Cellular Signalling · doi:10.1016/j.cellsig.2024.111110 · Cited by 23
Yang, H., Wang, J., Wang, W., Shi, S., Liu, L., Yao, Y., Tian, G., Wang, P., & Yang, J. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf209 · Cited by 25
Qu, X., Leung, T. C. N., Ngai, S. M., Tsai, S., Thakur, A., Li, W. K., Lee, Y., Leung, L. L., Ng, T. H., Yam, J. W. P., et al. (2021) · Cells · doi:10.3390/cells10092179 · Cited by 22
Prognostic Implications and Immune Infiltration Analysis of ALDOA in Lung Adenocarcinoma
Lu, G., Shi, W., & Zhang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.721021 · Cited by 22
MAP3K Family Review and Correlations with Patient Survival Outcomes in Various Cancer Types
Nguyen, K., Tran, M. N., Rivera, A., Cheng, T., Windsor, G. O., Chabot, A. B., Cavanaugh, J. E., Collins‐Burow, B. M., Lee, S. B., Drewry, D. H., et al. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2705167 · Cited by 25
Jee, H., Park, E., Hur, K., Kang, M., & Kim, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.818470 · Cited by 22
Bai, J., Zheng, A., Ha, Y., Xu, X., Yu, Y., Lu, Y., Zheng, S., Shen, Z., Luo, B., & Jie, W. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.988777 · Cited by 22
Bai, J., Tang, R., Zhou, K., Chang, J., Wang, H., Zhang, Q., Shi, J., & Sun, C. (2022) · BMC Medical Genomics · doi:10.1186/s12920-022-01380-z · Cited by 26
Jiang, R., Lu, B., Feng, F., Li, Q., Chen, X., Cao, S., Pan, Z., Deng, Z., Zhou, Y., Liu, P., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13402 · Cited by 22
Tan, X., Xiao, G.-Y., Wang, S., Shi, L., Zhao, Y., Liu, X., Jiang, Y. L., Russell, W. K., Creighton, C. J., & Kurie, J. M. (2023) · Journal of Clinical Investigation · doi:10.1172/jci165863 · Cited by 23
Ramasubramanian, A., Ramani, P., Kannan, B., & Arumugam, P. (2023) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13470 · Cited by 22
Eswaran, S., Padavu, M., Kumar, D., & Kabekkodu, S. P. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230816100623 · Cited by 21
Wu, R., Li, J., Aicher, A., Jiang, K., Tondi, S., Dong, S. L., Zheng, Q., Tang, S., Chen, M., Guo, Z., et al. (2024) · Advanced Science · doi:10.1002/advs.202308990 · Cited by 21
Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells
Strazza, M., Azoulay‐Alfaguter, I., Peled, M., Adam, K. R., & Mor, A. (2021) · Communications Biology · doi:10.1038/s42003-021-02225-8 · Cited by 21
TMEM229A suppresses non‑small cell lung cancer progression via inactivating the ERK pathway
Zhang, X., He, Y., Jiang, Y., Bao, Y., Chen, Q., Xie, D., Yu, H., & Wang, X. (2021) · Oncology Reports · doi:10.3892/or.2021.8127 · Cited by 21
Wang, J., Sun, Z., Wang, J., Tian, Q., Huang, R., Wang, H., Wang, X., & Han, F. (2021) · Cancer Medicine · doi:10.1002/cam4.4163 · Cited by 21
Huang, Z., Lai, H., Liao, J., Cai, J., Li, B., Meng, L.-H., Wang, W., Mo, X., & Qin, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.729230 · Cited by 21
Feng, L., Wang, J., Zhang, J., Diao, J., He, L., Fu, C., Liao, H., Xu, X., Gao, Y., & Zhou, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.738709 · Cited by 20
Kumar, S., Shuaib, M., Prajapati, K. S., Singh, A. K., Choudhary, P., Singh, S., & Gupta, S. (2022) · 3 Biotech · doi:10.1007/s13205-022-03140-3 · Cited by 21
Qin, S., Liu, G., Jin, H., Chen, X., Jiang, H., Xiao, J., Qin, Y., Mao, Y., & Zhao, L. (2022) · Disease Markers · doi:10.1155/2022/2676114 · Cited by 21
Basu, R., Qian, Y., Mathes, S. C., Terry, J., Arnett, N., Riddell, T., Stevens, A., Funk, K. R., Bell, S. R. C., Bokal, Z., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.936145 · Cited by 21
Yu, X., Shi, M., Wu, Q., Wei, W., Sun, S., & Zhu, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.891731 · Cited by 21
Modular scaffolding by lncRNA HOXA10-AS promotes oral cancer progression
Chen, Y., Kan, C.-H., Liu, H., Liu, Y., Wu, C., Kuo, Y., Chang, I. Y., Chang, K., Yu, J., & Tan, B. C. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05071-6 · Cited by 21
Dysregulated cholesterol regulatory genes as a diagnostic biomarker for cancer
Kuldeep, S., Soni, S., Srivastava, A., Mishra, A., Sharma, L. K., & Mandal, C. C. (2023) · The Journal of Gene Medicine · doi:10.1002/jgm.3475 · Cited by 21
Gao, Y. P., Yuan, L., Ke, C., Pei, Z., Liu, X., Wu, R., Kui, X.-Y., & Zhang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04001-0 · Cited by 21
A MAP1B–cortactin–Tks5 axis regulates TNBC invasion and tumorigenesis
Inoue, H., Kanda, T., Hayashi, G., Munenaga, R., Yoshida, M., Hasegawa, K., Miyagawa, T., Kurumada, Y., Hasegawa, J., Wada, T., et al. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.202303102 · Cited by 21
Wang, Q., Li, L., Gao, X., Zhang, C., Chen, X., Song, L., Li, J., Sun, X. G., Mao, F., & Wang, Y. (2024) · Advanced Science · doi:10.1002/advs.202304203 · Cited by 21
Lan, C., Liu, C., Nie, X., Lei, L., Xiao, Z.-X., Li, M., Tang, X.-N., Jia, M.-Y., & Xu, H. (2021) · Journal of Cancer · doi:10.7150/jca.62563 · Cited by 20
Yu, W., Liang, Z., Li, Q., Liu, Y., Liu, X., Jiang, L., Liu, C., Zhang, Y., Kang, C., & Yan, J. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115647 · Cited by 20
Wang, C., Lin, W.-H., Ku, S., Shen, W., Ta, H. D. K., Anuraga, G., Liu, F.-W., Shen, C.-F., Wang, S.-H., Yang, C., et al. (2022) · Aging · doi:10.18632/aging.204386 · Cited by 20
Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors
Chen, F., Byrd, A. L., Liu, J., Flight, R. M., DuCote, T. J., Naughton, K. J., Song, X., Edgin, A. R., Lukyanchuk, A., Dixon, D. T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35784-x · Cited by 21
Placental Galectins in Cancer: Why We Should Pay More Attention
Fuselier, C., Dumoulin, A., Paré, A., Nehmé, R., Ajarrag, S., de Boissel, P. G. J., Chatenet, D., Doucet, N., & St‐Pierre, Y. (2023) · Cells · doi:10.3390/cells12030437 · Cited by 20
Rupa, D., Chuang, H., Hu, C., Su, W., Wu, S., Lee, H., & Yuan, T. (2024) · Cancer Science · doi:10.1111/cas.16236 · Cited by 20
Huber, A., Allam, A. H., Dijkstra, C., Thiem, S., Huynh, J., Poh, A. R., Konecnik, J., Jacob, S. P., Busuttil, R. A., Liao, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114616 · Cited by 20
Kwon, J., Choi, H., Ware, A. D., Morillo, B. C., Wang, H., Bouker, K. B., Lu, X., Waldman, T. A., & Han, C. (2022) · Oncogene · doi:10.1038/s41388-022-02224-x · Cited by 20
Bao, L., Sun, K., & Zhang, X. (2021) · Channels · doi:10.1080/19336950.2021.2004758 · Cited by 19
A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer
Chang, Y.-T., Tsai, W., Lin, W.-Z., Wu, C., Yu, J.-C., Tseng, V. S. M., Liao, G., Hu, J., Hsu, H.-M., Chang, Y., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.759952 · Cited by 20
Tang, M., Chen, J., Zeng, T., Ye, D., Li, Y., Zou, J., & Zhang, Y. (2022) · Cancer Medicine · doi:10.1002/cam4.5238 · Cited by 19
METTL3 promotes drug resistance to oxaliplatin in gastric cancer cells through DNA repair pathway
Wang, Y., Hong, Z., Jintian, S., Zhong, P., & Lin, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1257410 · Cited by 19
Unbiased interrogation of functional lysine residues in human proteome
Bao, Y., Pan, Q., Xu, P., Liu, Z., Zhang, Z., Liu, Y., Xu, Y., Yu, Y., Zhou, Z. L., & Wei, W. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.033 · Cited by 19
Lefebvre, A., Trioën, C., Renaud, S., Laine, W., Hennart, B., Bouchez, C., Leroux, B., Allorge, D., Kluza, J., Werkmeister, E., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12390 · Cited by 19
MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA
Yang, Y., Tsai, M., Chang, Y., Wang, C., Chu, P., Lin, H., & Huang, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116001 · Cited by 19
Li, Y., Chen, X., Li, D., Yang, Z., Bai, Y., Hu, S., Liu, Z., Gu, J., & Zhang, X. (2021) · BMC Urology · doi:10.1186/s12894-021-00938-w · Cited by 19
You, G.-R., Chang, J. T., Li, Y.-L., Chen, Y., Huang, Y., Fan, K., Chen, Y.-C., Kang, C., & Cheng, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681717 · Cited by 18
Metadata
- Authors
- Nagy, Á., Munkácsy, G., & Győrffy, B.
- Affiliations
- Semmelweis University (HU)
- Corresponding author
- Győrffy, Balázs
- Venue
- Scientific Reports
- Published
- 2021-03-15
- Volume
- 11
- Issue
- 1
- Pages
- 6047-6047
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7961001
- OpenAlex
- W3139511935
- Cited by
- 1,381
- References
- 40
- Citations by year
- 2026: 38 · 2025: 84 · 2024: 145 · 2023: 504 · 2022: 311 · 2021: 298
- FWCI
- 101.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Semmelweis Egyetem
- Innovációs és Technológiai Minisztérium (ÚNKP-19-3, 2018-2.1.17-TET-KR-00001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- prognostic gene signature, survival analysis, genomic instability, invasion and metastasis, replicative immortality, cell death resistance, angiogenesis, tumor suppressor, BRCA1, RUNX1, SERPINE1, CDK1, E2F1, epiregulin, c-Myc, clear cell renal cell carcinoma, low-grade glioma, cervical cancer, bladder cancer, thyroid cancer, glioblastoma, tissue specificity, targeted therapy
- MeSH terms
- RNA-Seq, Humans, Neoplasms, Biomarkers, Tumor, Survival Rate, Disease-Free Survival, Databases, Nucleic Acid, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
